Aegerion Pharma (NASDAQ: AEGR) reported Q3 EPS of ($0.34), $0.08 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $67.3 million versus the consensus estimate of $59.72 million.

Aegerion Pharma sees FY2015 revenue of $230-245 million, versus the consensus of $239.1 million.

For earnings history and earnings-related data on Aegerion Pharma (AEGR) click here.